Today we’re addressing a fundamental challenge in pharmacological research: the molecular separation of ibogaine’s therapeutic effects from its concerning cardiac and neurological impacts. As of October 15, 2026, researchers are preparing U.S. government-funded clinical trials to investigate ibogaine for opioid use disorder, but serious safety concerns